Activating Effect of Benzbromarone, a Uricosuric Drug, on Peroxisome Proliferator-Activated Receptors

Chiyoko Kunishima, Ikuo Inoue, Toshihiro Oikawa, Hiromu Nakajima, Tsugikazu Komoda, and Shigehiro Katayama

1 Department of Pharmacovigilance, Torii Pharmaceutical Co., Ltd., 3-4-1 Nihonbashi-honcho, Chuo-ku, Tokyo 103-8439, Japan
2 Department of Internal Medicine, Faculty of Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan
3 Department of Clinical Laboratory, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka 537-8511, Japan
4 Department of Biochemistry, Faculty of Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan

Correspondence should be addressed to Toshihiro Oikawa, toshihiro.oikawa@torii.co.jp

Received 5 June 2007; Accepted 17 July 2007

Benzbromarone, a uricosuric drug, reportedly causes hepatic hypertrophy accompanied by proliferation of peroxisomes in rats. To elucidate the mechanisms underlying induction of peroxisome proliferation by benzbromarone, we examined binding affinity for peroxisome proliferator-activated receptor α (PPARα) and γ (PPARγ), and effects on the binding activity of PPARs with peroxisome proliferation-responsive element (PPRE) and expression of the PPARs target protein. Binding affinity of benzbromarone for PPARα and PPARγ was examined by reporter gene assay. Binding activity of PPARs with PPRE was determined by electric mobility shift assay, and expression of lipoprotein lipase (LPL) and acyl-CoA synthetase (ACS) by Western blot method. Benzbromarone displayed affinity for PPARα and PPARγ, and promoted binding of PPARs to PPRE. Furthermore, cultured cells with benzbromarone added showed upregulated expression of LPL and ACS. These results suggest that benzbromarone induces peroxisome proliferation in hepatocytes by binding to PPARs, and controls expression of proteins related to lipid metabolism.

Copyright © 2007 Chiyoko Kunishima et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Benzbromarone is a uricosuric drug that has been widely used for more than 25 years as a therapeutic agent for hyperuricemia. Recently, urate transporter 1 (URAT1) was identified in the luminal membrane of the proximal renal tubule, and the mechanism of action for benzbromarone was identified as suppression of uric acid resorption via inhibition of URAT1 [1]. Regarding the toxicity of benzbromarone, hypertrophy of the liver accompanied by proliferation of peroxisomes has been reported in a repeated-dose toxicity study in rats [2]. Similar changes have also been observed in studies on clofibrate and fenofibrate, both of which are antihyperlipemic drugs [2, 3]. Clofibrate and fenofibrate represent activators of peroxisome proliferator-activated receptor α (PPARα), and benzbromarone may similarly cause hypertrophy of the liver via actions on PPARα.

We have previously demonstrated that benzbromarone has affinity for PPARα and PPARγ, and upregulates expression of each protein [4]. In this study, to clarify the actions of benzbromarone on PPARs, the affinity of benzbromarone for PPARα and PPARγ was reexamined in comparison with a representative activator of each receptor. In addition, regarding the mechanism of gene expression induced by benzbromarone, binding between PPARs and peroxisome proliferator-responsive element (PPRE), and protein expressions of lipoprotein lipase (LPL), and acyl-CoA synthetase (ACS) encoded by the target gene of PPAR were examined.
Based on the findings, hepatic hypertrophy due to benzbromarone and the influence of benzbromarone on lipid metabolism are discussed.

2. MATERIALS AND METHODS

2.1. Chemicals

Benzbromarone, an active pharmaceutical ingredient of Uri-norm marketed by Torii Pharmaceutical Co., Ltd. (Tokyo, Japan), was used as a test compound in this study. Troglitazone, pioglitazone and fenofibric acid were synthesized at the Central Research Pharmaceutical Institute of Japan Tobacco Inc. (Osaka, Japan). Clofibric acid was purchased from Sigma-Aldrich Japan (Tokyo, Japan), nuclear and cytoplasmic extraction reagents from Pierce (Ill, USA), and a nucleic acid labeling kit from Molecular Probes (Ore, USA).

2.2. Cell culture

NIH/3T3 cells and human kidney 293T cells were maintained in D-MEM containing 10% fetal bovine serum, 50 U/mL penicillin and 50 μg/mL streptomycin at 37°C in a humidified 95% air and 5% CO2 atmosphere.

2.3. Reporter gene analysis

NIH/3T3 cells (0.4 × 10^5 cells/well) were cultured in 24-well plates for 20 hours and then transfected with a receptor plasmid for the chimera of PPARα or the PPARα ligand-binding domain and GAL4 DNA-binding domain, together with a receptor plasmid containing the GAL4-responsive promoter driving expression of luciferase. After 6 hours, cells were given fresh D-MEM containing test compounds at final concentrations of 0.001–100 μM, and were cultured for an additional 2 days. Benzbromarone, clofibric acid, fenofibric acid, troglitazone, and pioglitazone were suspended in 0.1% DMSO solution. After cells had been lysed, luciferase activity was determined using a CT-9000D luminometer (Dia-iatron, Tokyo, Japan).

A total of 3 measurements were performed for each batch of cultured cells per test, and a total of 3 tests were performed.

2.4. Electric mobility shift assay (EMSA)

First, following addition of benzbromarone at a final concentration of 1 μM, 293T cells were cultured for 24 hours. Cells were washed with TBS and pelleted by centrifugation at 1500×g for 5 minutes. Pellets were suspended in 1 mL TBS and transferred into an Eppendorf tube, then centrifuged again at 1000×g for 5 minutes to obtain pellets. Double-stranded oligonucleotides for sequences of the PPRE and mutant of PPRE were purchased from Santa Cruz Biotechnology (Calif, USA). Oligonucleotides were labeled with Alexa Flour 488 using a ULYSIS Nucleic Acid Labeling Kit (Molecular Probes). Labeled oligonucleotides (500 ng) were added to nuclear extracts. The binding assay buffer comprised 20 mM HEPES (pH 7.5) containing 40 mM KCl, 5% glycerol, and 1 μg dl-dC. Assay was performed at room temperature for 10 minutes at a final volume of 25 μL. Products of the binding reaction were separated on 5% polyacrylamide gel run in Tris-borate-EDTA at room temperature at 100 V for 60 minutes. Gels were visualized using a Fluorimager SI (Molecular Dynamics, Tokyo, Japan). This test was performed 6 times.

2.5. Western blot analysis

Benzbromarone was added to 293T cells to achieve a final concentration of 1 or 10 μM, and cells were cultured for 24 hours. Western blots for LPL and ACS proteins were then performed according to established procedures. Briefly, after cells (10^5 cells/well) had been suspended in lysis buffer (10 mM sodium phosphate, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 100 μg/mL PMSF, 30 μg/mL aprotinin, and 1 mM sodium orthovanadate, pH 7.4), aliquots of the cell suspension were obtained by repetitive pipetting and lysed by incubation at 4°C for 15 minutes. Lysed cells were centrifuged at 4000×g for 10 minutes, and the supernatant was separated by SDS-polyacrylamide gel electrophoresis in 10% acrylamide gel. The protein was transferred onto a nitrocellulose membrane and blocked for 60 minutes. The membrane was then incubated with anti-ACS (Japan Ram, Tokyo, Japan) or anti-LPL (Daiichi Pure Chemicals, Tokyo, Japan) antibodies. After washing, the membrane was incubated with horseradish peroxidase-conjugated antirabbit secondary antibodies (The Binding Site, Birmingham, UK). Chemiluminescence of bound antibodies was detected using a kit (Amersham BioSciences, NJ, USA). Protein contents were determined by the generally established method of Lowry using BSA as a standard. This test was performed 4 times.

3. RESULTS

The binding affinity of benzbromarone for PPARα and PPARγ was examined by reporter gene assay using transcriptional activity of the PPAR target gene as a marker, in comparison with those of clofibric acid, fenofibric acid, troglitazone, and pioglitazone (Figures 1 and 2). At 100 μM, benzbromarone induced an increase in luciferase activity, representing transcriptional activation of the target gene via binding of benzbromarone to PPARα, and the magnitude was nearly equal to that induced by clofibric acid, while fenofibric acid and pioglitazone induced transcriptional activation of the target gene at concentrations of ≥ 10 μM. Against PPARγ, benzbromarone induced an increase in luciferase activity at a concentration of 100 μM, troglitazone at ≥ 1 μM, and pioglitazone at ≥ 0.1 μM.

After adding benzbromarone to 293T cells, the nuclear extract was incubated with fluorescence-labeled PPRE oligonucleotide, and binding activity between PPARs and PPRE was determined by EMSA. Binding between PPARs and PPRE increased in cells with benzbromarone as compared to cells without benzbromarone (Figure 3). In addition, when mutant PPRE oligonucleotide was incubated with PPARs, no evidence of binding was found.

After addition of benzbromarone to 293T cells at final concentrations of 1 μM and 10 μM, LPL and ACS protein
expressions were determined using the western blot method, demonstrating a dose-dependent increase in each protein (Figure 4).

4. DISCUSSION

PPAR regulates transcriptional activation of the target gene by forming a heterodimer with the retinoid X receptor, and recognizing and binding to PPRE via a specific gene sequence [5]. Various proteins such as LPL, ACS, fatty acid transporter, and fatty acid binding protein have been reported to be expressed as a result of transcriptional activation of target genes by PPARs [6–8].

Clofibrate and fenofibrate as PPARα activators and troglitazone and pioglitazone as PPARγ activators are considered to affect the metabolism of lipids and carbohydrates in the living body through these processes [9–11]. The present studies were performed to elucidate the details of PPAR activation by benzbromarone, which has been shown to induce hepatic hypertrophy associated with peroxisomal proliferation in rats [2].

First, the ligand affinity of benzbromarone for PPARα was equivalent to that of clofibric acid, a representative activator of PPARα. The affinity of benzbromarone for PPARγ was weak and clearly inferior to the affinities of troglitazone and pioglitazone, which are representative activators of PPARγ. Second, benzbromarone added to 293T cells elicited an increase in specific binding between PPARs and PPRE. Third, benzbromarone enhanced protein expression of LPL and ACS in a concentration-dependent manner.

In addition, the last experiment revealed more marked enhancement of PPARα expression than PPARγ expression by benzbromarone [4]. Moreover, based on the results of in vitro and in vivo expression analyses of various

**Figure 1:** Effects of benzbromarone (•), troglitazone (○), pioglitazone (■), fenofibric acid (□), and clofibric acid (Δ) on PPARα activation. Cells were transfected with the receptor plasmid for the chimera of the PPARα ligand-binding domain and GAL4 DNA-binding domain, together with a reporter plasmid containing a GAL4-responsive promoter driving the expression of luciferase. Each point represents mean ± standard deviation (SD).

**Figure 2:** Effects of benzbromarone (•), troglitazone (○), pioglitazone (■), fenofibric acid (□), and clofibric acid (Δ) on PPARγ activation. Cells were transfected using the receptor plasmid for the chimera of the PPARγ ligand-binding domain and GAL4 DNA-binding domain, together with a reporter plasmid containing a GAL4-responsive promoter driving the expression of luciferase. Each point represents mean ± SD.

**Figure 3:** Comparative analysis of PPARs DNA-labeled PPRE complex by EMSA in nuclear extracts of 293T cells with or without benzbromarone treatment for 24 hours. Presence of PPRE was verified by incubation with mutant PPRE oligonucleotide.
PPARα-regulated genes in rats, benz bromarone has recently been classified as a PPARα agonist [12, 13]. The present findings support these reports from the perspective of intracellular gene transcription.

In patients receiving benz bromarone and in those receiving troglitazone, pioglitazone, clofibrate, fenofibrate, or other PPARs activators, hepatic impairment with an undeniable causal relationship to these drugs has been reported [14–17].

On the basis of the above findings and taking into account the mechanisms underlying increases in PPAR-mediated gene expression by PPARα activators such as clofibrate acid and fenofibrate acid and PPARα activators such as troglitazone and pioglitazone, we concluded that benz bromarone can be classified as a PPARα activator. The hepatic hypertrophy caused by benz bromarone in rats may thus be induced via enhancement of PPARα-mediated target gene expression and the resultant changes in lipid metabolism. In this context, the newly elucidated pharmacological features of benz bromarone could provide some hints that benz bromarone and other PPAR activators might display common mechanisms with relation to hepatic adverse effects.

The present study demonstrated that benz bromarone, a uricosuric drug, displays affinity for PPARs despite having a different chemical structure from fibrate-class antihyperlipemic drugs (fenofibrate, clofibrate) and thiazolidine-class antidiabetic drugs (troglitazone, pioglitazone), by comparison to these PPAR activators.

Considering that Cmax following oral administration of 100 mg benz bromarone in humans is approximately 5 μM [18], which is lower than levels in the present study, the present in vitro results may be difficult to simply extrapolate to clinical use. However, further investigations must be carefully conducted using the present findings as reference, into the relationships between benz bromarone and glucose and lipid metabolism, to reconfirm the clinical value of benz bromarone.
[12] N. Kiyosawa, K. Shiwaku, M. Hirode, et al., “Utilization of a one-dimensional score for surveying chemical-induced changes in expression levels of multiple biomarker gene sets using a large-scale toxicogenomics database,” *The Journal of Toxicological Sciences*, vol. 31, no. 5, pp. 433–448, 2006.

[13] K. Tamura, A. Ono, T. Miyagishima, T. Nagao, and T. Urushidani, “Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators,” *The Journal of Toxicological Sciences*, vol. 31, no. 5, pp. 471–490, 2006.

[14] E. H. Pierce and D. L. Chesler, “Possible association of granulomatous hepatitis with clofibrate therapy,” *The New England Journal of Medicine*, vol. 299, no. 6, p. 314, 1978.

[15] M. M. van der Klauw, P. M. Houtman, B. H. Ch. Stricker, and P. Spoelstra, “Hepatic injury caused by benz bromarone,” *Journal of Hepatology*, vol. 20, no. 3, pp. 376–379, 1994.

[16] K. G. Tolman and J. Chandramouli, “Hepatotoxicity of the thiazolidinediones,” *Clinics in Liver Disease*, vol. 7, no. 2, pp. 369–379, 2003.

[17] C.-Y. Ho, T.-H. Kuo, T.-S. Chen, S.-H. Tsay, F.-Y. Chang, and S.-D. Lee, “Fenofibrate-induced acute cholestatic hepatitis,” *Journal of the Chinese Medical Association*, vol. 67, no. 5, pp. 245–247, 2004.

[18] T. Oikawa, C. Kunishima, Y. Adachi, et al., “Metabolism study of benzbromarone: in vitro metabolism and pharmacokinetics in healthy volunteers,” *The Journal of New Remedies and Clinics*, vol. 53, no. 6, pp. 682–691, 2004 (Japanese).